Quick Answer
CytomX Therapeutics, Inc. reported Net Income of -$17.37 million for fiscal year 2025.
CytomX Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$17.37M | -154.5% |
| 2024 | $31.87M | +5700.9% |
| 2023 | -$569.0K | +99.4% |
| 2022 | -$99.32M | +14.3% |
| 2021 | -$115.87M | -252.3% |
| 2020 | -$32.88M | +67.8% |
| 2019 | -$102.24M | -20.8% |
| 2018 | -$84.60M | -96.3% |
| 2017 | -$43.10M | +26.8% |
| 2016 | -$58.90M | -66.5% |
| 2015 | -$35.37M | -16.7% |
| 2014 | -$30.31M | -100.2% |
| 2013 | -$15.14M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$14.23M | -348.1% | -9139.6% |
| June 30, 2025 | -$154.0K | +97.6% | -100.7% |
| March 31, 2025 | $23.52M | +70.6% | +310.1% |
| September 30, 2024 | $5.74M | +91.7% | +187.8% |
| June 30, 2024 | -$6.53M | -501.1% | -147.4% |
| March 31, 2024 | $13.79M | +516.5% | +360.9% |
| September 30, 2023 | $2.99M | +110.3% | +375.3% |
| June 30, 2023 | -$1.09M | +96.3% | +67.2% |
- CytomX Therapeutics, Inc. showed a decrease of -154.5% in Net Income compared to the prior fiscal year.
- Over the 2013–2025 period, CytomX Therapeutics, Inc.’s net income has declined by 14.7% (from -$15.14 million to -$17.37 million).
- The most recent figure is from CytomX Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: